Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENB 003

Next Previous
Drug Profile

ENB 003

Alternative Names: ENB-003; ENB-006

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ENB Therapeutics
  • Developer ENB Therapeutics; Merck AG
  • Class Amides; Antineoplastics; Indoles; Piperidines; Small molecules
  • Mechanism of Action Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • No development reported CNS cancer

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for research development in CNS-cancer in USA
  • 07 Nov 2023 Efficacy data from the phase Ib/IIa ENBOLDEN-101 trial in Ovarian cancer released by ENB Therapeutics
  • 18 Jul 2023 Efficacy and adverse events data from a phase I/IIa trial in Pancreatic cancer, Ovarian cancer, Malignant melanoma released by ENB Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top